Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Summary

The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization, psychiatric emergency room (ER) visit, crisis center visit, mobile crisis unit intervention, arrest/incarceration, and suicide or suicide attempt) in patients under their care during a 12 month period.

Conditions

• Schizophrenia

Interventions

OTHER

Caregiver psycho-education and skills training

Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.

OTHER

Caregiver support available at the study site

Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.

DRUG

Paliperidone palmitate

Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.

DRUG

Chlorpromazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Droperidol

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Fluphenazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Haloperidol

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Loxapine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Perphenazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Pimozide

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Prochlorperazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Thiothixene

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Thioridazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Trifluoperazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Aripiprazole

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Asenapine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Clozapine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Iloperidone

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Olanzapine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Paliperidone

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Quetiapine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Risperidone

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Ziprasidone

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Sponsors & Collaborators

• Janssen Scientific Affairs, LLC

  lead INDUSTRY

Principal Investigators

• Janssen Scientific Affairs, LLC Clinical Trial · Janssen Scientific Affairs, LLC

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-07-24

Primary Completion

2018-07-05

Completion

2018-07-05

Countries

• United States

Study Locations